期刊
PHARMACOGENOMICS
卷 18, 期 17, 页码 1557-1562出版社
FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2017-0110
关键词
FPGS; gene polymorphism; GGH; methotrexate; non-Hodgkin lymphoma; SLCO1B1; toxicity
资金
- Natural Science Foundation of Fujian Province [2016J01509]
- National Clinical Key Specialty Construction Program of China
Aim: To investigate the impact of polymorphisms in the FPGS, GGH and SLCO1B1 genes on high dose methotrexate (HD-MTX) related toxicity in Chinese patients with non-Hodgkin lymphoma (NHL). Materials & methods: We analyzed FPGS (rs10106), GGH (rs719235, rs10464903, rs12681874), SLCO1B1 (rs4149056) genetic polymorphisms in 105 Chinese patients with NHL treated with HD-MTX. Results: There was a statistically significant impact of the SLCO1B1 rs4149056 polymorphism on hepatotoxicity. Patients with TC and CC genotype had more hepatotoxicity than TT genotype (60 vs 32.94%, p = 0.025). After adjusting for disease stage, dosage, infusion time and therapy method, SLCO1B1 rs4149056 genotype remained significantly associated with hepatotoxicity (p = 0.028). Conclusion: SLCO1B1 rs4149056 genetic variants can affect the HD-MTX-related toxicity in Chinese patients with NHL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据